new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Taiho Pharmaceutical Co Ltd patents

Recent patent applications related to Taiho Pharmaceutical Co Ltd. Taiho Pharmaceutical Co Ltd is listed as an Agent/Assignee. Note: Taiho Pharmaceutical Co Ltd may have other listings under different names/spellings. We're not affiliated with Taiho Pharmaceutical Co Ltd, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Taiho Pharmaceutical Co Ltd-related inventors




Date Taiho Pharmaceutical Co Ltd patents (updated weekly) - BOOKMARK this page
03/09/17Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
03/02/17Stable crystal form of tipiracil hydrochloride and crystallization the same
02/16/17Novel acetic acid ester compound or salt thereof
02/16/17Preventive and/or therapeutic agent of immune disease
02/16/17Novel salt of fused pyrimidine compound and crystal thereof
02/09/17Detrusor hyperactivity with impaired contractility ameliorating agent
02/09/17Detrusor hyperactivity with impaired contractility ameliorating agent
11/24/16Azaindole derivative
10/27/16Novel tetrahydropyridopyrimidine compound or salt thereof
10/27/16Resistant mutant 90 kda heat shock protein
08/25/16Novel tetrahydropyridopyrimidine compound or salt thereof
08/18/16Novel peptide having 4 linked ctl epitopes
08/11/16Hla class i-expressing non-human animal
08/11/16Combination therapy using azabicyclo compound for cancer
08/11/16Novel piperidine compound or salt thereof
07/07/16Antitumor drug for intermittent administration of fgfr inhibitor
07/07/16Antitumor agent and antitumor effect enhancer
07/07/16Novel quinoline -substituted compound
06/02/16Oral particulate antitumor preparation
05/26/16Stable crystal form of tipiracil hydrochloride and crystallization the same
05/19/16Therapeutic agent for fgfr inhibitor-resistant cancer
04/28/16Novel fluorinated benzilic acid ester compound and salt thereof
04/28/16Novel fused pyrimidine compound or salt thereof
04/28/16Method for producng tricyclic compound, and tricyclic compound capable of being produced by said production method
04/14/16Method for predicting therapeutic efficacy of pi3k/akt/mtor inhibitor on basis of phlda1 or pik3c2b expression
03/24/16Antitumor agent including low-dose irinotecan hydrochloride hydrate
03/24/16Therapeutic effect prediction colorectal cancer patient in whom expression of tk1 protein has increased
02/18/16Antitumor agent including irinotecan hydrochloride hydrate
01/21/16Novel peptide having 5 linked ctl epitopes
10/22/15Pharmaceutical composition for oral administration with improved dissolution and/or absorption
09/10/15Weakly acidic ph-responsive peptide and liposome containing same
08/06/15Stable oxaliplatin-encapsulating liposome aqueous dispersion and stabilizing same
06/18/15Therapeutic agent for osteoporosis
06/18/15Antitumor effect potentiator composed of imidazooxazine compound
04/23/15Novel antitumor agent comprising combination of three agents
04/02/15Agent for improving vesicourethral dyssynergia
03/05/15Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a treatment of tumor
02/19/15Prophylactic agent and/or therapeutic agent for stress urinary incontinence
02/12/15Novel piperidine compound or salt thereof
01/01/15Recombinant prpk-tprkb and uses thereof
12/25/14Effect potentiator for antitumor agents
12/18/14Novel acetic acid ester compound or salt thereof
12/11/14Oral pharmaceutical composition
12/04/14Oral administrable pharmaceutical composition
11/20/141,2,4-triazine-6-carboxamide derivative
11/13/14Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
10/09/14Azabicyclo compound and salt thereof
07/31/14Antitumor agent and therapeutic effect prediction patients with kras-mutated colorectal cancer
05/08/14Piperazine compound capable of inhibiting prostaglandin d synthase
04/17/14Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
02/27/14Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
02/13/14Nanoparticles containing ph-responsive peptide
02/06/14Tegafur-containing composition for single daily and alternate-day dosing
01/02/14Novel imidazo-oxazine compound or salt thereof
11/07/13Novel bicyclic compound or salt thereof
10/31/13Novel indole or indazole derivative or salt thereof
06/27/13Prostaglandin d synthase inhibitory piperidine compounds
05/09/13Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
03/28/13Oral particulate antitumor preparation
12/06/12Piperazine compound having a pgds inhibitory effect
09/06/12Anti-tumor effect potentiator
06/21/12Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
05/03/12Azabicyclo compound and salt thereof
04/26/12Method for predicting therapeutic effect of chemotherapy on renal cell cancer
03/08/12Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
Patent Packs
01/12/12Potentiator of radiation therapy
12/29/11Piperazine compound capable of inhibiting prostaglandin d synthase
09/01/11Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same
07/14/11Antitumor agent containing 4 - [[3,5 - bis (trimethylsilyl) benzoyl] amino] benzoic acid
06/09/11Antitumor agent, kit and treating cancer
04/21/11Potentiator for radiation therapy comprising pyridine derivative as active ingredient
04/07/11Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
02/10/11Acylthiourea compound or salt thereof, and use thereof
02/10/11Iontophoresis preparation for treating breast cancer and/or mastitis
12/30/10Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
10/21/10Oral particulate antitumor preparation
09/23/10Phophylactic or therapeutic agent for inflamatory disease comprising thymidine phosphorylase inhibitor as active ingredient
09/02/10Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
08/26/102'-cyanopyrimidine nucleoside compound
08/19/10Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
Patent Packs
05/13/10Cytidine derivative-containing antitumor agent for continuous intravenous administration
03/11/10Method for predicting efficacy of rar-alpha agonist
12/24/09Postoperative adjuvant chemotherapy for gastric cancer
12/10/093'-ethynylcytidine derivative
11/19/09Potentiator of radiation therapy
11/12/09Therapeutic agent for hypertension
11/12/09Radiotherapy enhancer
11/12/09Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
10/08/09Process for production of steroid compound
08/20/09Assay human orotate phosphoribosyltransferase protein
08/20/09Therapeutic agent for inflammatory bowel disease







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Taiho Pharmaceutical Co Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Taiho Pharmaceutical Co Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';